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Introduction: Renal transplant subjects are considered at risk for the development of obesity and changes
in lipid and glucose metabolism because of the use of immunosuppressive medications.This study was
aimed at assessing the prevalence of metabolic syndrome in renal transplant recipients and to identify
factors associated with its occurrence.
Materials and methods: A cross-sectional study was conducted recruiting renal transplant patients. The
metabolic syndrome (MS) was diagnosed according to the criteria of the 2004 revision of ATP III criteria.
Results: MS was found in 43/132 (32.5%) of participants. Also, it was found in 18/70 (25.7%) of males,
which was signiﬁcantly lesser than that found in female 25/62 (40.3%) (po0.05). hypertension is the
commonest criteria of MS as it was found in 31/43 (72%) of the recruited sample.
Conclusions: MS is common in the recruited sample here in Iraq. Preventive measures should be taken to
prevent such an issue and its related complications.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Metabolic syndrome (MS) consists of a cluster of certain clinical
traits with metabolic and hemodynamic alterations. This includes
abdominal obesity, high blood pressure, insulin resistance (IR), and
dyslipidemia, which individually or in combination increase the
risk for developing overt diabetes [1], cardiovascular disease (CVD)
[2], chronic kidney disease (CKD) [3,4] and cardiovascular mor-
tality [5]. MS affects 44% of the united states population older than
50 years old and it is more prevalent in female than male. The age
dependency of the syndrome's prevalence is seen in most popu-
lations around the world [6]. Risk factors for MS include abdom-
inal obesity, IR, physical inactivity, aging, and hormonal imbalance.
A diet rich in saturated fat and cholesterol can predispose to the
developing CVD in people with the MS [7].
MS is continuously increasing in the general population, how-
ever, its prevalence and consequences in subjects with renal
transplantation is not well established [8]. Cardiovascular diseases
are the primary cause of morbidity and death in solid organ
transplant recipients. Risk factors that contribute to the higher
cardiovascular risk in the transplant population include hy-
pertension and dyslipidemia that may be pre-existent to and be-
come more severe after transplantation. Additionally, overweight,
obesity and post-transplant diabetes mellitus, which may appear
as a consequence of immunosuppression, play a role.Inc. This is an open access article uImmunosuppressant and corticosteroids may aggravate hy-
pertension and lipid abnormality and may predispose to new-
onset diabetes after transplantation. In addition, weight increase is
almost a consistent after transplant [9]. The MS is associated with
graft dysfunction and decreased survival among renal transplant
recipients [8,10–15].
The aim of this study was to assess the prevalence of metabolic
syndrome in renal transplant recipients and to identify factors
associated with its occurrence.2. Methods
This cross sectional study was conducted in Duhok Kidney
Disease Center starting from 1st April, 2013 to 30th April, 2015.
Participants were randomly select with history of more than one
year of live-donor kidney transplantation. Immunosuppressive
regimen comprised induction with Basiliximab, followed by
maintenance therapy with calcineurin inhibitor (tacrolimus or
cyclosporine), mycophenolate mofetil and prednisolone.
Personal health data including past medical history, family
history of chronic illnesses, drugs history and immunosuppressive
protocol were also collected.
Blood pressure was assessed as the average of two measure-
ments taken after subjects had been seated for at least 5 minutes
[16]. Resting systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were measured by using sphygmomanometer and
cuffs appropriate for arm size. The following parameters werender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Participants characteristics.
Variable MS (n═43) Non-MS
(n¼89)
P value
Age of recipient (year) 36714 34715 0.45
Male (%) 21 (48) 49 (55) 0.25
Female (%) 22 (51) 40(45) 0.25
Mean duration of hemodialysis (year) 1.1 1.3 o0.05
Waist circumference (M4102 cm,
F488 cm) (%)
27 (63) 29(33) o0.001
Obese (%) 15(35) 10(11) o0.001
Hypertension (%) 31 (72) 29 (32) o0.001
Hypertriglyceridemia (%) 27 (62) 19(21) o0.001
Low HDL-CH (%) 22 (51) 23(26) o0.05
Regular exercise (%) 7(16) 22(25) 0.13
eGFR (mL/min/1.73 m2) (%) 7174.3 8175.2 o0.001
Table 2
Patient with different Criteria of MS.
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 Hypertension: was deﬁned as a SBP Z 140 mmHg and DBP Z
90 mmHg or use of antihypertensive therapy [17].
 Waist Circumference: The WC is measured at the widest part
of the abdomen at the end of a relaxed exhalation, cut off value
for males 4 102 cm, female 4 88 cm were considered obese
[18].
 Physical activity: Scale was constructed by considering the
responses to questions on job of participants and how many
hours per day of activity, which is divided into active and se-
dentary activity [19].
 Metabolic Syndrome: According to the 2004 revision of ATP III
criteria, kidney transplant recipient were classiﬁed as having
the MS or not. By ATP III criteria, MS is deﬁned as having 3 or
more of the followings:
1. WC4102 cm in men or 488 cm in women;
2. Triglyceride (TGs)Z150 mg/dL or drug treatment for elevated
TGs;
3. High density lipoprotein –Cholesterol (HDL-CH)o40 mg/dL in
men or o50 mg/dL in women or drug treatment for elevated
HDL-CH;
4. SBP Z130 mm Hg, DBP Z85 mm Hg, or use of antihypertensive
therapy; and
5. Fasting glucose Z100 mg/dL or use of anti-diabetics [20].Table 3
distribution of MS and non-MS according to age group.
Age (Year) Total no. MS (%) Non-MS (%)
o30 30 7 (23% ) 23 (77%)
30–39 43 13 (30%) 30 (70%)3. Ethics
The nature of the study was explained to the participants and
oral consent was obtained from all of them. The study protocol
was approved by Research committee of School of Medicine-Fa-
culty of Medical Sciences-Duhok University.40–49 41 14(34%) 27 (66%)
Z50 18 9 (50% ) 9(50%)
Total 132 43 89
Table 4
Crude prevalence of metabolic syndrome and its components as deﬁned by Na-
tional Cholesterol Education Program–Adult Treatment Panel III criteria.4. Statistics
All the data analysis was performed using Excel 2010. Sig-
niﬁcance of association between various risk factors was assessed
using Chi-square and student T tests and the level of statistical
signiﬁcance was set at o 0.05.Component Crude prevalence (%) P value
Total Men (70) Women (62)
Central obesity 56 18 38 o0.001
Low HDL-cholesterol 45 21 24 0.14
High TG 46 28 17 o0.05
Hypertension 60 31 27 0.46
Hyperglycaemia 24 11 13 0.057
Metabolic syndrome 43 18 25 o0.055. Results
5.1. Patients' characteristics
We investigated 132 renal transplant recipients at a median
time of 2.1 (1–3.6) years post-transplant. Among these, 72 subjects
were males and 60 were females. The mean age of the participant
was 36 years (Table 1).5.2. Determinants of MS
In this study and according to the revised ATP III criteria, it was
found that 43/132 (32.5%) of participants had MS (Table 2). Also, it
was found that the highest MS rate was found in subjects older
than 50 years old (Table 3). We then stratiﬁed our data according
to gender. MS was found in 18/70 (25.7%) of the male which was
signiﬁcantly lesser than that found in female 25/62 (40.3%)
(po0.05). Central obesity was more prevalent in 38/62 (61.2%)
females than that found in males 18/70 (25.7%) (po0.001) (Ta-
ble 4). Additionally, high TG levels were higher in female than
male (po0.05) (Table 4).Seventeen of the participants had a history of diabetes before
renal transplantation and seven new cases were diagnosed post
renal transplantation with higher occurrence among Tacrolimus
based immunosuppressant group. The data were then stratiﬁed
according to the immunosuppressant medications. The prevalence
of patients with hyperglycaemia was higher in subjects receiving
tacrolimus than that receiving cyclosporine (po0.05). No other
signiﬁcant differences were found (Fig. 1).6. Discussion
In the general population, the prevalence of MS differs widely
among ethnic groups and depending on the deﬁnition of MS.
Fig. 1. Criterion of MS according to immunosuppressant.
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dysfunction and graft loss and new diabetes in the renal transplant
population. In our study the prevalence of MS was found to be
32.5%, while the prevalence of metabolic syndrome varied widely
from as low as 14.9% to as high as 63% which may reﬂect the
difference in populations studied. In a study conducted in Brazil,
MS was found in 44.8% of renal transplant recipients while the
prevalence of in Spain was lower and shown to be 37.7% of the
patients. In Japan, different studies shown different results de-
pending upon the criteria deﬁning MS. The variation in Japan
ranged from 14.9 to 23.8%. Moreover, in the Netherlands, 63% of
the renal transplant recipients evaluated are presented MS
[10,15,21–23]. These difference may be related to differences in
lifestyle, eating habits, the prevalence and degree of obesity or the
selection criteria.
In a previous study where the association between MS and GFR
in renal transplant recipients was studied, no signiﬁcant associa-
tion between the GFR and MS was found [10]. Surprisingly, in this
study, the levels of GFR were lower in the MS group. This is dif-
ﬁcult to explain and more studies are needed to explore this. One
explanation was that the sample size used in the study.
Seventeen of the participants had a history of diabetes before
renal transplantation and seven new cases were diagnosed post
renal transplantation with higher occurrence among the tacroli-
mus based immunosuppressant group. This is difﬁcult to explain
and more studies are needed to explore this.
In a study conducted in Brazil, hypertension was found as the
most common cardiovascular and renal risk factor for MS and it
was found in 97.4 and 87.5% of renal transplant recipients with and
without MS, respectively [10]. In agreement with this, we found
that hypertension is the commonest criteria of MS. However,
others found that waist circumference was the commonest cri-
terion [24]. It was previously shown that in the general population,
age is an independent risk factor of MS. In this study, the highest
rate of MS was found in patients older than 50 years old.
Additionally, the MS prevalence was higher in female and this
probably is related to the higher obesity and dyslipidemia rates
found in women. The high prevalence rate of MS in female was
also shown in Iranian, Chinese, Spanish and Pakistan studies
[15,25–27] and in contrast to Japanese and Netherland studies
[10,28].
7. Conclusion
We found that MS is highly prevalent among kidney transplant
recipients particular among females. As cardiovascular disease isthe leading cause of mortality in kidney transplant recipients,
accounting for over 50% of deaths, therefore, it is crucial to identify
the clinical predictors and/or risk factors MS pre-transplantation
which may help for early diagnosis and provide guidance for ap-
propriate therapeutic intervention.References
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